We Claim:

1. A method comprising: providing a compound of the formula:



wherein R^{N1} is a substituent of formula G^1-NX^1X^2, wherein G^1 is an optionally further substituted alkylene, which optionally forms, together with R^{N2}, a cyclo ring, R^{N2} is H or together with R^{N1} forms a cyclo ring and each of X^1 and X^2 is independently H or an N-substituent, or X^1 and X^2 together form a heterocyclic ring, or X^1 together with G^1 forms a cyclic group and X^2 is H or an N-substituent; and each of Z^1, Z^2, Z^3 and Z^4 is independently H or a substituent, or two of Z^1, Z^2, Z^3 and Z^4 together form an optionally substituted ring, and further wherein at least one of Z^1, Z^2, Z^3 and Z^4 is other than H; and administering an amount of said compound or pharmaceutically acceptable salts thereof to a subject.

2. The method of claim 1, wherein said method further comprises obtaining an HCV titer of said subject.

3. The method of claim 1, wherein said subject is an animal.

4. The method of claim 1, wherein said subject is a mammal.

5. The method of claim 1, wherein said subject is a human.

6. The method of claim 1, wherein said subject is in need of treatment or prophylaxis of HCV.

7. The method of claim 1, wherein said compound is administered to said subject in an anti-HCV effective amount.

8. A compound of the following formula:



wherein R^{N1} is a substituent of formula G^1-NX^1X^2, wherein G^1 is an optionally further substituted alkylene, which optionally forms, together with R^{N2}, a cyclo ring, R^{N2} is H or together with R^{N1} forms a cyclo ring and each of X^1 and X^2 is independently H or an N-substituent, or X^1 and X^2 together form a heterocyclic ring, or X^1 together with G^1 forms a cyclic group and X^2 is H or an N-substituent; and each of Z^1, Z^2, Z^3 and Z^4 is independently H or a substituent, or two of Z^1, Z^2, Z^3 and Z^4 together form an optionally substituted ring, and further wherein at least one of Z^1, Z^3 and Z^4 is other than H; and further where Z^2 is other than H and pharmaceutically acceptable salts thereof.

9. The compound of claim 8, having the formula:



wherein G^2 is O, S, NH, NR^{N7}, or CH_2, and R^{N7} is alkyl or acyl; Ak^1 is optionally substituted alkylenyl or together with R^{N5} or R^{N6} forms a ring, Ak^2 is alkylenyl or together with one of R^{N3} or R^{N4} forms a heterocyclyl ring, R^{N3} is H or a substituent or together with Ak^2 forms said heterocyclyl ring, R^{N4} is H or a substituent or together with Ak^2 forms said heterocyclyl ring, or together R^{N3} and R^{N4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents.

10. The compound of claim 9, having the formula:



wherein each of R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents.

11. The compound of claim 9, wherein G^2 is O.

12. The compound of claim 9, wherein each of R^{N3}, R^{N4}, R^{N5} and R^{N6} is C_1-C_6 alkyl.

13. The compound of claim 9, wherein each of R^{N3}, R^{N4}, R^{N5} and R^{N6} is methyl.

14. The compound of claim 8, having the formula:



wherein q is 0 or 1, p is 0 or 1, Ak^1 is optionally further substituted alkylenyl, or together with R^{N5} or R^{N6} forms a heterocyclyl ring, Ak^3 is optionally further substituted alkylenyl, or together with R^{N3} or R^{N4} forms a heterocyclyl ring, R^{N3} is H or a substituent or together with Ak^3 forms a heterocyclyl ring, R^{N4} is H or a substituent or together with Ak^3 forms a heterocyclyl ring, or together R^{N3} and R^{R4} form a cyclyl ring that is optionally further substituted with one or more substituents; R^{N5} is H or a substituent or together with Ak^1 forms a heterocyclyl ring, R^{N6} is H or a substituent is H or a substituent or together with Ak^1 forms a heterocyclyl ring, or together R^{N5} and R^{N6} form a heterocyclyl ring that is optionally further substituted with one or more substituents; R^a is H or a substituent and R^b is H or a substituent.

15. The compound of claim 8, having the formula:



,

wherein q is 0 or 1, p is 0 or 1, Ak^1 is optionally further substituted alkylenyl, or together with R^{N5} or R^{N6} forms a heterocyclyl ring, Ak^3 is optionally further substituted alkylenyl, or together with R^{N3} or R^{N4} forms a heterocyclyl ring, R^{N3} is H or a substituent or together with Ak^3 forms a heterocyclyl ring, R^{N4} is H or a substituent or together with Ak^3 forms a heterocyclyl ring, or together R^{N3} and R^{R4} form a cyclyl ring that is optionally further substituted with one or more substituents; R^{N5} is H or a substituent or together with Ak^1 forms a heterocyclyl ring, R^{N6} is H or a substituent is H or a substituent or together with Ak^1 forms a heterocyclyl ring, or together R^{N5} and R^{N6} form a heterocyclyl ring that is optionally further substituted with one or more substituents; R^a is H or a substituent and R^b is H or a substituent.

16. The compound of claim 8, having the formula:



,

wherein m is 0 or 1, n is 0 or an integer of from 1 to 6, p is 0 or 1, Ak^1 is optionally further substituted alkylenyl, or together with R^{N5} or R^{N6} forms a heterocyclyl ring, Ak^3 is optionally further substituted alkylenyl, or together with R^{N3} or R^{N4} forms a heterocyclyl ring, R^{N3} is H or a substituent or together with Ak^3 forms a heterocyclyl ring, R^{N4} is H or a substituent or together with Ak^3 forms a heterocyclyl ring, or together R^{N3} and R^{R4} form a cyclyl ring that is optionally further substituted with one or more substituents; R^{N5} is H or a substituent or together with Ak^1 forms a heterocyclyl ring, R^{N6} is H or a

substituent is H or a substituent or together with Ak^1 forms a heterocyclyl ring, or together R^{N5} and R^{N6} form a heterocyclyl ring that is optionally further substituted with one or more substituents; R^a is H or a substituent and R^b is H or a substituent.

17. The compound of claim 8, having the formula:



wherein m is 0 or 1, n is 0 or an integer of from 1 to 3, p is 0 or 1, Ak^1 is optionally further substituted alkylenyl, R^{N3} is H or a substituent and R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; and each of Z^1, Z^3 and Z^4 is H or C_1-C_3 alkyl.

18. The compound of claim 17, wherein each of R^{N3}, R^{N4}, R^{N5} and R^{N6} is C_1-C_6 alkyl.

19. The compound of claim 17, wherein each of R^{N3}, R^{N4}, R^{N5} and R^{N6} is methyl.

20. The compound of claim 17, wherein R^{N3} is H or a substituent; R^{N4} is H or a substituent, R^{N5} is H and R^{N6} is a heterocyclyl moiety, which is optionally further substituted.

21. The compound of claim17, wherein R^{N3} is H or a substituent; R^{N4} is H or a substituent, R^{N5} is H and R^{N6} is a piperidin-4-yl or pyrrolidin-2-yl, which is optionally further substituted.

22. The compound of claim17, wherein R^{N3} is H or a substituent; R^{N4} is H or a substituent, R^{N5} is H and R^{N6} is piperidin-4-yl or pyrrolidin-2-yl, which is optionally further substituted.

23. The compound of claim 17, wherein R^{N3} is H or a substituent; R^{N4} is H or a substituent, R^{N5} is H and R^{N6} is a heterocyclyl moiety, which is further substituted with a benzyl group.

24. The compound of claim 17, wherein R^{N3} is alkyl and R^{N4} is alkyl.

25. The compound of claim 17, wherein R^{N3} is methyl and R^{N4} is methyl.

26. The compound of claim 17, wherein R^{N5} and R^{N6} together form a heterocyclyl ring, which is optionally further substituted.

27. The compound of claim 17, wherein R^{N5} and R^{N6} together form a piperidinyl ring, which is optionally further substituted.

28. The compound of claim 17, wherein R^{N5} and R^{N6} together form a piperidinyl ring, which is substituted with a heterocyclyl moiety.

29. The compound of claim 17, wherein R^{N5} and R^{N6} together form a piperidinyl ring, which is substituted with a pyrrolidinyl moiety.

30. The compound of claim 17, wherein R^{N5} is alkyl.

31. The compound of claim 17, wherein R^{N6} is substituted alkyl.

32. The compound of claim 17, wherein R^{N6} is substituted alkyl, which is substituted with a saturated or unsaturated heterocyclyl moiety, which heterocylyl moiety is optionally further substituted.

33. The compound of claim 17, wherein R^{N6} is substituted alkyl, which is substituted with a saturated or unsaturated heterocyclyl moiety, which heterocylyl moiety is optionally further substituted with an alkyl, Cl, Br, or hydroxymethyl group.

34. The compound of claim 17, wherein R^{N6} is substituted alkyl, which is substituted with a fully unsaturated heterocyclyl moiety, which heterocylyl moiety is optionally further substituted.

35. The compound of claim 17, wherein R^{N6} is substituted alkyl, which is substituted with a fully unsaturated heterocyclyl moiety, which heterocylyl moiety has from 5 to 8 ring members, of which 1 to 3 ring members are N, O or S, and which heterocyclyl is optionally further substituted.

36. The compound of claim 17, wherein R^{N6} is substituted alkyl, which is substituted with a fully unsaturated heterocyclyl moiety, which heterocylyl is an optionally further substituted pyrrolyl, pyrenyl, imidazolyl, pyridinyl, pyrazinyl, pyrimidinyl, furanyl, pyranyl, thiophenyl, thiopyranyl, thiazolyl, oxazolyl, azepinyl, or diazepinyl.

37. The compound of claim 17, wherein R^{N6} is substituted alkyl, which is substituted with a member of the group consisting of an optionally substituted pyrrolyl, an optionally substituted pyridinyl, an optionally substituted furanyl, an optionally substituted thiophenyl and an optionally substituted thiazolyl.

38. The compound of claim 17 wherein R^{N3} and R^{N4} combine to form a heterocyclyl ring, which is optionally further substituted.

39. The compound of claim 17, wherein R^{N3} and R^{N4} combine to form a heterocyclyl ring, which is an optionally further substituted pyrrolidin-1-yl, piperidiny-1-yl, N-morpholino, N-thiomorpholino, homopiperidiny-1-yl, N-homomorpholino or N-homothiomorpholino.

40. The compound of claim 8, having the formula:



wherein each of R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents.

41. The compound of claim 8, having the formula:



wherein G^2 is O, S, NH, NR, or CH_2, t is 0 or 1, w is 0 or 1, R^c is H or a substituent, R^d is H or a substituent, is C_1-C_6 alkylenyl, which is optionally further substituted; Ak^4 is C_1-C_6 alkylenyl, which is optionally further substituted; R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents.

42. The compound of claim 8, having the formula:



wherein Ak^2 is C_1-C_6 alkylenyl, which is optionally further substituted; Ak^4 is C_1-C_6 alkylenyl, which is optionally further substituted; R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents.

43. The compound of claim 8, having the formula:



wherein Ak^2 is C_1-C_6 alkylenyl, which is optionally further substituted; Ak^4 is C_1-C_6 alkylenyl, which is optionally further substituted; R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and

R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents.

44. The compound of claim 8, having the formula:



wherein Ak^2 is C_1-C_6 alkylenyl, which is optionally further substituted; Ak^4 is C_1-C_6 alkylenyl, which is optionally further substituted; R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents.

45. The compound of claim 44, wherein R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents.

46. The compound of claim 44, wherein R^{N3} is H or alkyl and R^{N4} is H or alkyl.

47. The compound of claim 44, wherein R^{N3} is H or C_1-C_3 alkyl and R^{N4} is H or C_1-C_3 alkyl.

48. The compound of claim 44, wherein R^{N3} is H and R^{N4} is H.

49. The compound of claim 44, wherein R^{N3} is methyl and R^{N4} is methyl.

50. The compound of claim 44, wherein R^{N5} is H or alkyl and R^{N6} is H or alkyl.

51. The compound of claim 44, wherein R^{N5} is H or C_1-C_3 alkyl and R^{N6} is H or C_1-C_3 alkyl.

52. The compound of claim 44, wherein R^{N5} is H and R^{N6} is H.

53. The compound of claim 44, wherein R^{N5} is methyl and R^{N6} is methyl.

54. The compound of claim 44, wherein Ak is methylenyl or ethylenyl.

55. The compound of claim 44, wherein Ak is methylenyl.

56. The compound of claim 44, wherein Ak is ethyleneyl.

57. The compound of claim 44, wherein R^{N5} is H or alkyl and R^{N6} is optionally substituted alkyl.

58. The compound of claim 44, wherein R^{N5} is alkyl and R^{N6} is substituted alkyl.

59. The compound of claim 44, wherein R^{N5} is alkyl and R^{N6} is alkyl substituted with $NR^{N7}R^{N8}$, wherein R^{N7} is H or alkyl and R^{N8} is H or alkyl.

60. The compound of claim 44, wherein R^{N5} is H or alkyl and R^{N6} is alkyl substituted with an optionally further substituted heterocyclyl group.

61. The compound of claim 44, wherein R^{N5} is alkyl and R^{N6} is alkyl substituted with an optionally further substituted fully unsaturated heterocyclyl group.

62. The compound of claim 44, wherein R^{N6} is alkyl substituted with an optionally further substituted fully unsaturated heterocyclyl having from 5 to 8 ring members, of which 1 to 3 are members of the group consisting of N, S and O, wherein the N may have a H to complete its valency requirement, or be further substituted with an alkyl group.

63. The compound of claim 44, wherein R^{N6} is alkyl substituted with an optionally further substituted heterocyclyl having from 5 to 7 ring members and 1 to 2 nitrogens in the ring.

64. The compound of claim 44, wherein R^{N6} is alkyl substituted with an optionally further substituted pyrrolyl or imidazolyl.

65. The compound of claim 44, wherein R^{N6} is alkyl substituted with an N-alkyl-2-pyrrolyl.

66. The compound of claim 44, wherein R^{N6} is alkyl substituted with imidazol-2-yl.

67. The compound of claim 44, wherein R^{N6}, together with the N to which it is attached, forms a guanidino group.

68. The compound of claim 8, having the formula:



wherein G^2 is O, S, NH, NR^{N7}, or CH_2; Ak^2 is C_1-C_6 alkylenyl, which is optionally further substituted; Ak^4 is C_1-C_6 alkylenyl, which is optionally further substituted; R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; and R^d is H or a substituent; Z^3 is H or a substituent, Z^4 is H or a substituent; and R^{N7} is alkyl or acyl.

69. The compound of claim 8, having the formula:



wherein Ak^2 is C_2-C_4 alkylenyl, which is optionally further substituted; Ak^4 is C_1-C_3 alkylenyl, which is optionally further substituted; R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; Z^3 is H, alkyl, CF_3, F, Cl or Br; Z^4 is H, alkyl, CF_3, F, Cl or Br; and R^d is H or alkyl.

70. The compound of claim 69, wherein R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents.

71. The compound of claim 69, wherein R^{N3} is H or alkyl and R^{N4} is H or alkyl.

72. The compound of claim 69, wherein R^{N3} is H or C_1-C_3 alkyl and R^{N4} is H or C_1-C_3 alkyl.

73. The compound of claim 69, wherein R^{N3} is H and R^{N4} is H.

74. The compound of claim 69, wherein R^{N3} is methyl and R^{N4} is methyl.

75. The compound of claim 69, wherein R^{N5} is H or alkyl and R^{N6} is H or alkyl.

76. The compound of claim 69, wherein R^{N5} is H or C_1-C_3 alkyl and R^{N6} is H or C_1-C_3 alkyl.

77. The compound of claim 69, wherein R^{N5} is H and R^{N6} is H.

78. The compound of claim 69, wherein R^{N5} is methyl and R^{N6} is methyl.

79. The compound of claim 69, wherein Ak is methylenyl or ethylenyl.

80. The compound of claim 69, wherein Ak is methylenyl.

81. The compound of claim 69, wherein Ak is ethyleneyl.

82. The compound of claim 69, wherein R^{N5} is H or alkyl and R^{N6} is optionally substituted alkyl.

83. The compound of claim 69, wherein R^{N5} is alkyl and R^{N6} is substituted alkyl.

84. The compound of claim 69, wherein R^{N5} is alkyl and R^{N6} is alkyl substituted with $NR^{N7}R^{N8}$, wherein R^{N7} is H or alkyl and R^{N8} is H or alkyl.

85. The compound of claim 69, wherein R^{N5} is H or alkyl and R^{N6} is alkyl substituted with an optionally further substituted heterocyclyl group.

86. The compound of claim 69, wherein R^{N5} is alkyl and R^{N6} is alkyl substituted with an optionally further substituted fully unsaturated heterocyclyl group.

87. The compound of claim 69, wherein R^{N6} is alkyl substituted with an optionally further substituted fully unsaturated heterocyclyl having from 5 to 8 ring members, of which 1 to 3 are members of the group consisting of N, S and O, wherein the N may have a H to complete its valency requirement, or be further substituted with an alkyl group.

88. The compound of claim 69, wherein R^{N6} is alkyl substituted with an optionally further substituted heterocyclyl having from 5 to 7 ring members and 1 to 2 nitrogens in the ring.

89. The compound of claim 69, wherein R^{N6} is alkyl substituted with an optionally further substituted pyrrolyl or imidazolyl.

90. The compound of claim 69, wherein R^{N6} is alkyl substituted with an N-alkyl-2-pyrrolyl.

91. The compound of claim 69, wherein R^{N6} is alkyl substituted with imidazol-2-yl.

92. The compound of claim 69, wherein R^{N6}, together with the N to which it is attached, forms a guanidino group.

93. The compound of claim 8, having the formula:



,

wherein Ak is C_1-C_6 alkylene, which is optionally further substituted; R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; each of R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents.

94. The compound of claim 8, having the formula:



wherein g is 0 or 1; f is 0 or 1; Z^3 is H or a substituent; Z^4 is H or a substituent; Y^1 is Ak^3-$NR^{N3}R^{N4}$ or $NR^{N3}R^{N4}$, wherein Ak^3 is alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is Ak^4-$NR^{N5}N^{N6}$ or $NR^{N5}R^{N6}$, wherein Ak^4 is alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; G^2 is O, S, NH, NR^{N7} or CH_2, wherein R^{N7} is alkyl or acyl.

95. The compound of claim 8, having the formula:



,

wherein g is 0 or 1; f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is Ak^4-$NR^{N5}N^{N6}$, wherein

Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents.

96. The compound of claim 8, having the formula:



,

wherein one of R^c, R^d and R^e is Y^1, wherein Y^1 is Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents, and the other two of R^c, R^d and R^e are each independently H or a substituent; and one of R^f, R^g and R^h is Y^2, wherein Y^2 is $NR^{N5}R^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents, and the other two of R^f, R^g and R^h are independently H or a substituent.

97. The compound of claim 96, wherein R^c is Y^1.

98. The compound of claim 96, wherein R^d is Y^1.

99. The compound of claim 96, wherein R^e is Y^1.

100. The compound of claim 96, wherein Y^1 is $NR^{N3}R^{N4}$.

101. The compound of claim 96, wherein R^{N3} is H, alkyl, substituted alkyl, cycloalkyl substitued cycloalkyl, heterocyclyl or substituted heterocyclyl.

102. The compound of claim 96, wherein R^{N4} is alkyl.

103. The compound of claim 96, wherein R^{N3} and R^{N4}, together to the N to which they are attached, form an optionally substituted heterocyclyl group.

104. The compound of claim 96, wherein Y^1 is $Ak^3NR^{N3}R^{N4}$.

105. The compound of claim 96, wherein Ak^3 is C_1-C_6 alkylenyl.

106. The compound of claim 96, wherein Ak^3 is methylenyl or ethylenyl.

107. The compound of claim 96, wherein Z^3 is H or alkyl.

108. The compound of claim 96, wherein Z^4 is H or alkyl.

109. The compound of claim 96, wherein R^f is Y^2.

110. The compound of claim 96, wherein R^g is Y^2.

111. The compound of claim 96, wherein R^h is Y^2.

112. The compound of claim 96, wherein Y^2 is $NR^{N5}R^{N6}$.

113. The compound of claim 96, wherein Y^2 is $Ak^4NR^{N5}R^{N6}$.

114. The compound of claim 96, wherein Ak^4 is C_1-C_6 alkylene.

115. The compound of claim 96, wherein Ak^4 is methylenyl, ethylenyl or 1,3-propylenyl.

116. The compound of claim 8, having the formula:



wherein one of R^c, R^d and R^e is wherein Y^1 is Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents, and the other two of R^c, R^d and R^e are each independently H or a substituent; and one of R^g and R^h is Y^2, wherein Y^2 is $NR^{N5}R^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents, and the other of R^g and R^h is H or a substituent.

117. The compound of claim 116, wherein R^c is Y^1.

118. The compound of claim 116, wherein R^d is Y^1.

119. The compound of claim 116, wherein R^e is Y^1.

120. The compound of claim 116, wherein Y^1 is $NR^{N3}R^{N4}$.

121. The compound of claim 116, wherein R^{N3} is H, alkyl, substituted alkyl, cycloalkyl substitued cycloalkyl, heterocyclyl or substituted heterocyclyl.

122. The compound of claim 116, wherein R^{N4} is alkyl.

123. The compound of claim 116, wherein R^{N3} and R^{N4}, together to the N to which they are attached, form an optionally substituted heterocyclyl group.

124. The compound of claim 116, wherein Y^1 is $Ak^3NR^{N3}R^{N4}$.

125. The compound of claim 116, wherein Ak^3 is C_1-C_6 alkylenyl.

126. The compound of claim 116, wherein Ak^3 is methylenyl or ethylenyl.

127. The compound of claim 116, wherein Z^3 is H or alkyl.

128. The compound of claim 116, wherein Z^4 is H or alkyl.

129. The compound of claim 116, wherein R^g is Y^2.

130. The compound of claim 116, wherein R^h is Y^2.

131. The compound of claim 116, wherein Y^2 is $NR^{N5}R^{N6}$.

132. The compound of claim 116, wherein Y^2 is $Ak^4NR^{N5}R^{N6}$.

133. The compound of claim 116, wherein Ak^4 is C_1-C_6 alkylene.

134. The compound of claim 116, wherein Ak^4 is methylenyl, ethylenyl or 1,3-propylenyl.

135. The compound of claim 8, having the formula:



,

wherein one of R^d and R^e is wherein Y^1 is Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents, and the other of R^d and R^e is H or a substituent; and one of R^f, R^g and R^h is Y^2, wherein Y^2 is $NR^{N5}R^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents, and the other two of R^f, R^g and R^h are independently H or a substituent.

136. The compound of claim 135, wherein R^d is Y^1.

137. The compound of claim 135, wherein R^e is Y^1.

138. The compound of claim 135, wherein Y^1 is $NR^{N3}R^{N4}$.

139. The compound of claim 135, wherein R^{N3} is H, alkyl, substituted alkyl, cycloalkyl substitued cycloalkyl, heterocyclyl or substituted heterocyclyl.

140. The compound of claim 135, wherein R^{N4} is alkyl.

141. The compound of claim 135, wherein R^{N3} and R^{N4}, together to the N to which they are attached, form an optionally substituted heterocyclyl group.

142. The compound of claim 135, wherein Y^1 is $Ak^3NR^{N3}R^{N4}$.

143. The compound of claim 135, wherein Ak^3 is C_1-C_6 alkylenyl.

144. The compound of claim 135, wherein Ak^3 is methylenyl or ethylenyl.

145. The compound of claim 135, wherein Z^3 is H or alkyl.

146. The compound of claim 135, wherein Z^4 is H or alkyl.

147. The compound of claim 135, wherein R^f is Y^2.

148. The compound of claim 135, wherein R^g is Y^2.

149. The compound of claim 135, wherein R^h is Y^2.

150. The compound of claim 135, wherein Y^2 is $NR^{N5}R^{N6}$.

151. T he compound of claim 135, wherein Y^2 is $Ak^4NR^{N5}R^{N6}$.

152. The compound of claim 135, wherein Ak^4 is C_1-C_6 alkylene.

153. The compound of claim 135, wherein Ak^4 is methylenyl, ethylenyl or 1,3-propylenyl.

154. The compound of claim 8, having the formula:



,

wherein one of R^d and R^e is wherein Y^1 is Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents, and the other of R^d and R^e is H or a substituent; and one of R^g and R^h is Y^2, wherein Y^2 is $NR^{N5}R^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents, and the other of R^g and R^h is H or a substituent.

155. The compound of claim 154, wherein R^d is Y^1.

156. The compound of claim 154, wherein R^e is Y^1.

157. The compound of claim 154, wherein Y^1 is $NR^{N3}R^{N4}$.

158. The compound of claim 154, wherein R^{N3} is H, alkyl, substituted alkyl, cycloalkyl substitued cycloalkyl, heterocyclyl or substituted heterocyclyl.

159. The compound of claim 154, wherein R^{N4} is alkyl.

160. The compound of claim 154, wherein R^{N3} and R^{N4}, together to the N to which they are attached, form an optionally substituted heterocyclyl group.

161. The compound of claim 154, wherein Y^1 is $Ak^3NR^{N3}R^{N4}$.

162. The compound of claim 154, wherein Ak^3 is C_1-C_6 alkylenyl.

163. The compound of claim 154, wherein Ak^3 is methylenyl or ethylenyl.

164. The compound of claim 154, wherein Z^3 is H or alkyl.

165. The compound of claim 154, wherein Z^4 is H or alkyl.

166. The compound of claim 154, wherein R^g is Y^2.

167. The compound of claim 154, wherein R^h is Y^2.

168. The compound of claim 154, wherein Y^2 is $NR^{N5}R^{N6}$.

169. T he compound of claim 154, wherein Y^2 is $Ak^4NR^{N5}R^{N6}$.

170. The compound of claim 154, wherein Ak^4 is C_1-C_6 alkylene.

171. The compound of claim 154, wherein Ak^4 is methylenyl, ethylenyl or 1,3-propylenyl.

172. The compound of claim 8, having the formula:



wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^d is H or a substituent.

173. The compound of claim 8, having the formula:



wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^d is H or a substituent; R^f is H or a substituent; R^g is H or a substituent.

174. The compound of claim 8, having the formula:



wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^d is H or a substituent; R^f is H or a substituent.

175. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^d is H or a substituent; R^g is H or a substituent.

176. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^d is H or a substituent; R^g is H or a substituent; R^h is H or a substituent.

177. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more

substituents; R^c is H or a substituent; R^d is H or a substituent; R^f is H or a substituent; R^g is H or a substituent.

178. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^d is H or a substituent; R^f is H or a substituent; R^g is H or a substituent.

179. The compound according to claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^d is H or a substituent; R^f is H or a substituent.

180. The compound of claim 8, having the formula:



.

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or

Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^d is H or a substituent; and R^g is H or a substituent.

181. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^d is H or a substituent; R^g is H or a substituent; and R^h is H or a substituent.

182. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^d is H or a substituent; R^f is H or a substituent; R^g is H or a substituent

183. The compound of claim 8 having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent.

184. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^f is H or a substituent; and R^g is H or a substituent.

185. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^f is H or a substituent; and R^h is H or a substituent.

186. The compound of claim 8, having the formula:



wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^g is H or a substituent; and R^h is H or a substituent.

187. The compound of claim 8, having the formula:



wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^g is H or a substituent.

188. The compound of claim 8, having the formula:



wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^f is H or a substituent.

189. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^f is H or a substituent; R^g is H or a substituent.

190. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^f is H or a substituent; R^h is H or a substituent.

191. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or

together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^g is H or a substituent; R^h is H or a substituent.

192. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^g is H or a substituent.

193. The compound of claim 8, having the formula:



,

wherein f is 0 or 1; Z^3 is H or alkyl; Z^4 is H or alkyl; Y^1 is $NR^{N3}R^{N4}$ or Ak^3-$NR^{N3}R^{N4}$, wherein Ak^3 is C_1-C_3 alkylenyl, R^{N3} is H or a substituent, R^{N4} is H or a substituent, or together R^{N3} and R^{R4} form a cyclic moiety that is optionally further substituted with one or more substituents; Y^2 is $NR^{N5}N^{N6}$ or Ak^4-$NR^{N5}N^{N6}$, wherein Ak^4 is C_1-C_3 alkylenyl, R^{N5} is H or a substituent, R^{N6} is H or a substituent, or together R^{N5} and R^{N6} form a cyclic moiety that is optionally further substituted with one or more substituents; R^c is H or a substituent; R^f is H or a substituent.

194. The compound according to claim 8, having one of the following structures:



,



,



,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



195. A method comprising administering to a subject a compound of claim 8.

196. A method comprising administering to a subject an amount of the compound according to claim 8 effective to reduce the viral load of HCV in the subject.

197. A method of affecting HCV replication comprising:

contacting a region of a HCV RNA with a composition, wherein said region of the HCV RNA is region IIa of the HCV IRES; and

affecting thereby replication of said HCV.

198. The method according to claim 197 wherein the composition comprises a compound according to claim 8 or a pharmaceutically acceptable salt thereof.

199. The method according to claim 197 wherein region IIa includes residues 52-65 and residues 102-111 of the HCV RNA 5-UTR.

200. A method of affecting HCV replication comprising:

contacting a region IIa of a HCV RNA with a composition having a binding affinity for said region of < 50 μM; and

affecting thereby replication of said HCV.

201. The method according to claim 200 wherein the composition comprises a compound according to claim 8 or a pharmaceutically acceptable salt thereof.

202. The method according to claim 200 wherein the region is IIa of the HCV RNA 5-UTR and includes residues 52-65 and residues 102-111 of the HCV RNA 5-UTR.

203. A method of affecting HCV replication *in vitro* comprising:

contacting *in vitro* a region of a HCV RNA with a composition having a binding affinity for said region of < 50 μM, wherein said region of the HCV RNA is region IIa and has a stem secondary structure; and

affecting thereby replication of said HCV.

204. The method according to claim 203 wherein the composition comprises a compound according to claim 8 or a pharmaceutically acceptable salt thereof.

205. A method of affecting HCV replication *in vivo* comprising:

contacting *in vivo* a region of a HCV RNA with a composition having a binding affinity for said region of < 50 μM, wherein said region of the HCV RNA is region IIa and includes residues 52-65 and residues 102-111 of the HCV RNA 5-UTR; and

affecting thereby replication of said HCV.

206. The method according to claim 205 wherein the composition comprises a compound according to claim 8 or a pharmaceutically acceptable salt thereof.

207. A method comprising:

contacting a composition with a region of a HCV RNA wherein said region of the HCV RNA is region IIa and has a stem secondary structure and includes residues 52-65 and residues 102-111 of the HCV RNA 5-UTR; and

quantifying said composition's affect on HCV replication.

208. The method according to claim 207 wherein the composition comprises a compound according to claim 8 or a pharmaceutically acceptable salt thereof.

209. The method according to claim 207 wherein said contacting is *in vivo*.

210. The method according to claim 207 wherein said contacting is *in vitro*.